With Gileads Yescarta and Bristol Myers Squibbs Breyanzi showing that Car-T might replace stem cell transplant in second-line lymphoma, one question is why Novartiss Kymriah failed in precisely this setting. Todays Ash late-breaking presentation provided some clues.
Excuses notwithstanding, the bottom line is that Novartis will not file Kymriah for this early use, the Swiss firm confirmed to Evaluate Vantage. A bigger question is whether the strong event-free survival benefit shown in Yescarta and Breyanzis corresponding successful trials is enough to see these two competitors filed and approved for use in the second-line setting.
Presentation at Ash of detailed data from all three studies in question, Breyanzis Transform, Yescartas Zuma-7, and Kymriahs Belinda, has made the possibility of Car-T replacing second-line stem cell transplantation in lymphoma one of the biggest topics of this years meeting. Each trial compared Car-T against standard of care, meaning chemotherapy followed by transplant in patients who go into remission.
Crossover conundrum
But a key issue has emerged, in that a majority of patients in the control cohorts of these three trials crossed over to Car-T on disease progression as part of protocol in Transform and Belinda, and off-protocol in Zuma-7. Thus the EFS metric loses importance if an absence of overall survival benefit suggests that patients relapsing on second-line standard of care can still be rescued by Car-T in its currently approved third-line setting.
The jury is still out on whether this is the case. Both the successful trials, Transform and Zuma-7, showed an immature OS analysis numerically favouring Breyanzi and Yescarta, the former with widening survival curves, admittedly from an interim analysis.
But Zuma-7s primary investigator, Dr Frederick Locke from Moffitt Cancer Center, told Sundays Ash plenary session that treatment switching in the standard-of-care cohort was likely confounding a significant OS benefit.
However, for her part University of Colorado Cancer Centers Dr Manali Kamdar, who presented the Transform data on Saturday, said patients who got Breyanzi later (after crossing over from standard of care) did not do as well as those who got it earlier. This appears to back the importance of giving Breyanzi second rather than third line.
However this plays out, it will be up to regulators to determine whether the EFS benefits Bristol and Gilead have shown are enough to secure second-line approvals in the absence of a mature OS analysis. The EFS findings themselves show Yescarta and Breyanzi beating second-line standard of care by a huge margin, cutting risk of progression by over 60%.
Moderating a press briefing, Dr Laurie Sehn of University of British Columbia said it was inevitable that [Car-T] will become the standard of care in second-line lymphoma. Without being drawn on which therapy was better, she noted that the Zuma-7 data were very mature, while Transforms was an interim analysis.
Belindas bust
One Car-T therapy that will not be moving up is Novartiss Kymriah, whose Belinda study was already known to be a bust. Some blame for this has been placed on the fact patients given Kymriah were more sick than those in the control cohort.
But speaking to Vantage Stefan Hendriks, Novartiss head of cell and gene, also said time from randomisation to infusion was longer in Belinda than in the other two trials. This has been an ongoing problem for Novartis, and while it was partly down to Covid-19 and capacity constraints the upshot is that some patients did not get Kymriah in time, and saw their disease get worse.
Investigators said time from leukapheresis to infusion of Car-T cells, including lymphodepletion, was on average 52 days in Belinda, versus just 29 in Zuma-7.
Another quirk was that Novartis capped EFS assessment at 12 weeks. Some patients Mr Hendriks did not say how many responded to Kymriah after this point, but because they had stable or progressive disease at 12 weeks they were nevertheless counted as having evented.
Still, Mr Hendricks was clear: Because of the outcome of [Belinda] we will not submit for a second-line indication. But he said a pivotal second-line lymphoma trial would be carried out with YTB323, a next-generation Car-T that can be manufactured within two days.
Breyanzi safer?
Over the weekend discussion turned to fault lines emerging between the two successful studies, Transform and Zuma-7. A key matter appears to be safety: while both trials saw a similar amount of severe all-cause treatment-related adverse events, severe cytokine release syndrome (CRS) and neurotoxicity was lower in Transform than in Zuma-7.
Dr Kamdar said this made Breyanzi appealing not just from a standpoint of efficacy but also [from its] extremely tolerable safety. Only one Breyanzi patient had grade 3 CRS, and there was no grade 4 or 5 CRS or neurotoxicity. There was one Car-T treatment-related death in each of the two studies.
Other differences were that Transform allowed patients with a broader histology profile than Zuma-7, and it did, like Belinda, allow bridging chemo while the Car-T cells were being produced. Zuma-7 allowed steroids during this phase, but, crucially, not chemo.
In a cutting remark, Dr Locke stated: We wanted to know: could [Yescarta] be given without the confounding effect of chemotherapy, which we know can cause a response?
One remaining problem is what to do once a second-line lymphoma patient on Car-T does relapse. Both presenters said there was no appropriate standard of care here, but said a small number of such relapsing patients in both studies ended up getting transplanted; in Zuma-7 this amounted to 19 patients, nine of whom are still alive, said Dr Locke.
No matter, the argument shifts to whether, given Car-Ts better efficacy, payers should shell out for this rather than stem cell transplant. Dr Kamdar said it was too early to talk of financial toxicity, but stressed Car-Ts potential as a once and done therapy. Dr Locke said some of the intensive hospital care costs were similar in transplantation and Car-T.
The efficacy data seem pretty clear, so the ball now enters the court of the FDA on whether to approve, and of payers to decide whether to pay up.
Go here to read the rest:
Ash 2021 why Breyanzi and Yescarta might refresh the parts Kymriah cannot reach - Vantage
- Biology of stem cells: an overview - PMC - National Center for ... - March 26th, 2024
- Iron Limitation Preserves Youthfulness of Blood Stem Cells - Mirage News - March 13th, 2024
- Mini organs grown from stem cells of unborn babies for the first time in breakthrough - The Mirror - March 9th, 2024
- The Effect of Short-Term NAD3 Supplementation on Circulating Adult Stem Cells in Healthy Individuals Aged 40-70 ... - Cureus - March 7th, 2024
- University of Liverpool Spin-Out Emerges, Pioneering Novel Adult Stem Cell-Based Therapies - India Education Diary - March 7th, 2024
- Scientists have used cells from fluid drawn during pregnancy to grow mini lungs and other organs - Yahoo News Canada - March 6th, 2024
- Japan approves new stem cell-based Alzheimer's therapy By Proactive Investors - Investing.com Australia - January 20th, 2024
- Cyberstalking pits Harvard professor against PubPeer Retraction ... - Retraction Watch - December 5th, 2023
- 10 functional health predictions for 2024, according to a doctor and ... - 1330 WFIN - December 5th, 2023
- See the Brain Like Never Before in This Gorgeous Art - Scientific American - December 5th, 2023
- Geron Announces Publication in The Lancet of Results from the ... - BioSpace - December 5th, 2023
- Stem cell injections could be the key to curing MS - Freethink - December 3rd, 2023
- Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the ... - Investors | Eli Lilly and Company - December 3rd, 2023
- Comparative Efficacy and Safety of Four JAK Inhibitors for ... - HealthDay - December 3rd, 2023
- City lights up for Francis on Anthony Nolan's birthday - Liverpool Express - December 3rd, 2023
- NOT-AR-23-022: Request for Information on Themes for the NIAMS ... - National Institutes of Health (.gov) - December 3rd, 2023
- December 2023: Intramural Papers of the Month - Environmental Factor Newsletter - December 1st, 2023
- CNA Explains: What is cord blood banking and why do parents do it? - CNA - December 1st, 2023
- Regulation of myogenesis and adipogenesis by the electromagnetic ... - Nature.com - December 1st, 2023
- The effects of vitamin K on bone health - News-Medical.Net - December 1st, 2023
- Dr Hurwitz on Ongoing Investigations of the Use of CAR T-Cell ... - OncLive - December 1st, 2023
- Mitophagy in human health, ageing and disease - Nature.com - December 1st, 2023
- Adult Stem Cells - Stem Cells and the Future of Regenerative Medicine ... - November 29th, 2023
- Navigating The Regulatory Landscape Of Longevity Health Products ... - Mondaq News Alerts - November 29th, 2023
- MS breakthrough could lead to treatments that halt disease's ... - inews - November 29th, 2023
- Reprogramming tissue mechanically to promote wound healing - Phys.org - November 29th, 2023
- Latest Advances in Arthritis Diagnosis and Treatment at American ... - HealthDay - November 29th, 2023
- Sex-associated differences in frequencies and prognostic impact of ... - Nature.com - November 29th, 2023
- Hematologists Dive into the Current Treatment Landscape - OncLive - November 29th, 2023
- Team discovers protein crucial for B cell differentiation and antibodies - Phys.org - November 29th, 2023
- Science Talk - I survived cancer as a child and now I'm working to ... - The Institute of Cancer Research - November 29th, 2023
- First Edition: Nov. 29, 2023 - KFF Health News - November 29th, 2023
- Symptoms: Unilateral Hearing Loss and Tinnitus : The Hearing Journal - LWW Journals - November 29th, 2023
- Mitigation of sepsis-induced acute lung injury by BMSCs | IJN - Dove Medical Press - November 29th, 2023
- A Case of a Constricted Vessel: The Impact of Acute Myeloid ... - Cureus - November 29th, 2023
- Mum brushed off fatigue after having baby but fall sparked deadly diagnosis - The Mirror - November 29th, 2023
- How heritable is the epigenome? - Drug Discovery News - November 29th, 2023
- The Blueprint of Regeneration: Scientists Discover How to Turn Stem Cells Fate - Revyuh - November 27th, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - Marketscreener.com - November 27th, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - PharmiWeb.com - November 25th, 2023
- COVID-19 Pandemic's Adverse Effect on Bone Health in Young ... - HealthDay - November 25th, 2023
- Sickle cell breakthrough - The Indian Express - November 25th, 2023
- Wall thickness analysis method for judging the degree of lower ... - Nature.com - November 25th, 2023
- Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - Yahoo Finance - November 23rd, 2023
- Disease Transmission and Diagnosis of Zika Virus - Cureus - November 23rd, 2023
- Gene-editing therapy for sickle cell earns conditional approval in UK - Sickle Cell Disease News - November 23rd, 2023
- Stem Cell Therapy Developed in Korea Begins Treatment for ... - Newswire - November 21st, 2023
- Efficacy of ADSC-CM in Patients with Telogen Effluvium | SCCAA - Dove Medical Press - November 21st, 2023
- BrainStorm Cell Therapeutics Announces In-Person Meeting with ... - PR Newswire - November 21st, 2023
- The Impact of CAR T Cell Therapy on Managing R/R LBCL - OncLive - November 21st, 2023
- Mansour bin Zayed witnesses inauguration of ADSCC Bone Marrow Transplant & Cellular Therapy Congress 2023 - ZAWYA - November 21st, 2023
- Listeria: Who is most susceptible? What are the Symptoms? What ... - Food Poison Journal - November 21st, 2023
- Scope Of Issued Patents May Be Limited By Prosecution Estoppel ... - Mondaq News Alerts - November 21st, 2023
- Qrons Announces the Addition of Professor Shiri Navon-Venezia to ... - StreetInsider.com - November 21st, 2023
- Financially strapped Athersys raises $10.4M - cleveland.com - November 19th, 2023
- From the India Today archives (2010) | How stem cells can save your life - India Today - November 19th, 2023
- Inactivation of the tumor suppressor gene Apc synergizes with H ... - Science - November 19th, 2023
- The Origins of Multiple Myeloma and Why it Matters - HealthTree For AML - Acute Myeloid Leukemia - November 19th, 2023
- Treatment Considerations With TROP2-Targeted Therapy - OncLive - November 19th, 2023
- Athersys narrows loss, raises $10.4 million during third quarter to ... - The Business Journals - November 17th, 2023
- Who was Dolly the Sheep and what happened to her? The story of ... - BBC Countryfile Magazine - November 17th, 2023
- UK first to approve CRISPR treatment for diseases: what you need to ... - Nature.com - November 17th, 2023
- 1st sickle cell patient to be given therapy restoring fetal hemoglobin - Sickle Cell Disease News - November 15th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - Century - Benzinga - November 13th, 2023
- Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer - Yahoo Finance - November 11th, 2023
- Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in... - November 11th, 2023
- AAO 2023: Paul Runge and his ROP treatments in the Ukraine - Modern Retina - November 11th, 2023
- The Evolutionary Reasons We Are Drawn To Horror Movies and ... - Slashdot - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - GlobeNewswire - November 11th, 2023
- Century Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 9th, 2023
- NYU Langone Health Performs World's First Whole-Eye & Partial ... - NYU Langone Health - November 9th, 2023
- BrainStorm to Announce Third Quarter 2023 Financial Results and ... - BioSpace - November 9th, 2023
- Can we cut cost and pain of IVF? Start-up CEO tries out own ... - Genetic Literacy Project - November 9th, 2023
- Jasper Therapeutics Reports Third Quarter 2023 Financial Results ... - BioSpace - November 9th, 2023
- Impaired neural stress resistance and loss of REST in bipolar ... - Nature.com - November 9th, 2023
- Functional genomics and systems biology in human neuroscience - Nature.com - November 9th, 2023
- Trial launched to test CAR T-cell therapy in dogs diagnosed with ... - EurekAlert - November 9th, 2023
- The-Gut's-Lasting-Impact-on-Severe-COVID-19-Immune-Response - Infectious Disease Special Edition - November 9th, 2023
- Emerging Cure for Sickle Cell on its Way to FDA Approval, Carries ... - Dallasweekly - November 7th, 2023
- The science works, but will we pay for it? - Irish Medical Times - November 7th, 2023
Recent Comments